10-K: PetMed Express Restates Financials, Leadership Changes Amidst Internal Probe

PetMed Express, Inc. has filed a comprehensive annual report on Form 10-K, restating prior financial statements due to accounting errors and announcing significant leadership changes following an internal audit committee investigation.

Summary

• The company restated financial statements for fiscal years ended March 31, 2024, and 2023, and interim periods within FY2023, FY2024, and FY2025, due to income statement classification errors related to vendor-funded programs; these corrections did not impact net income, balance sheets, cash flows, or shareholder equity.
• An Audit Committee investigation, concluded on October 7, 2025, found accelerated AutoShip product shipments, misclassified coupon expenses, undisclosed related-party hiring by the former CEO, and delayed reporting of whistleblower complaints by the former Audit Committee Chair and CFO.
• Sales decreased by $47.1 million, or 17.2%, to $227.0 million for the fiscal year ended March 31, 2025, compared to $274.1 million in the prior year.
• New customer acquisition declined significantly to 351,000 in FY2025 from 457,000 in FY2024.
• Gross profit decreased by $15.6 million, or 18.4%, to $69.1 million in FY2025, with the gross profit margin declining to 30.5% from 30.9%.
• Adjusted EBITDA saw a substantial decrease of 92%, falling to $672 thousand in FY2025 from $8.245 million in FY2024.
• The company reported a net loss of $6.3 million in FY2025, an improvement from the $7.5 million loss in FY2024.
• Material weaknesses in internal control over financial reporting were identified, leading to an adverse opinion from the independent registered public accounting firm, RSM US LLP.
• A $1.2 million impairment loss was recognized on the PetCareRx trade name in FY2025.
• The company suspended its quarterly dividend indefinitely as of February 1, 2024, to focus cash flow on growth initiatives.

Sentiment

Score: 3

Explanation: The company experienced a significant decline in sales and profitability, a restatement of prior financials due to accounting errors, and an adverse opinion on internal controls. An internal investigation uncovered serious governance and operational issues, including revenue recognition manipulation and related-party hiring. While management is implementing remediation plans and the company maintains a strong cash position, the extent of the issues and the negative financial performance warrant a low sentiment score.

Positives

• Net loss decreased by $1.2 million in FY2025 compared to FY2024, indicating some improvement in bottom-line performance despite revenue challenges.
• Average order value increased slightly to $97 in FY2025 from $94 in FY2024.
• Recurring sales, including AutoShip and membership revenue, as a percentage of total gross sales, increased to 56.1% in Q4 FY2025 from 53.5% in Q4 FY2024, demonstrating customer loyalty to subscription programs.
• The company is implementing strategic initiatives to enhance customer experience, optimize operational efficiency, and leverage innovation for long-term shareholder value.
• Investments are being made in modernizing technology, e-commerce infrastructure, and cloud environments to support future growth.
• Expansion into multi-channels, including Amazon, and new compound pharmacy partnerships are underway, along with the planned introduction of private label functional health products in late FY2026.
• The company maintains a strong cash position of $54.7 million and has no debt obligations as of March 31, 2025.
• Comprehensive remediation plans are being implemented to address identified material weaknesses in internal controls, including ITGCs, income and sales taxes, complex accounting matters, control environment, revenue recognition, and cooperative advertising/vendor reimbursements.

Negatives

• The company restated previously issued financial statements for multiple periods due to income statement classification errors, impacting investor confidence.
• An Audit Committee investigation revealed significant governance and operational issues, including accelerated AutoShip product shipments, misclassified coupon expenses, undisclosed related-party hiring by the former CEO, and delayed reporting of whistleblower complaints by former executives.
• Sales decreased substantially by 17.2% to $227.0 million in FY2025, driven by declines in both reorder sales (15.5%) and new order sales (25.5%).
• New customer acquisition fell significantly from 457,000 in FY2024 to 351,000 in FY2025.
• Gross profit decreased by 18.4% and the gross profit margin declined from 30.9% to 30.5% in FY2025.
• Adjusted EBITDA plummeted by 92% to $672 thousand in FY2025, indicating severe pressure on operational profitability.
• The company received an adverse opinion from its auditors on the effectiveness of its internal control over financial reporting due to identified material weaknesses.
• A $1.2 million impairment loss was recognized on the PetCareRx trade name in FY2025.
• The quarterly dividend has been suspended indefinitely since February 1, 2024, reducing direct shareholder returns.
• The company is facing ongoing class-action lawsuits alleging misrepresentation of product prices and discounts.

Risks

• Any failure to comply with various state or federal regulations covering the pet health business, including prescription dispensing, may subject the company to reprimands, sanctions, fines, suspensions, or loss of pharmacy licenses.
• Improper inventory management could lead to excessive carrying costs or inadequate product supply, materially affecting financial condition and results of operations.
• Resistance from veterinarians to authorize prescriptions or efforts to discourage pet owners from purchasing from the company could cause sales to decrease.
• Loss of pharmacy licenses in key states (Florida, California, Texas, New York, Pennsylvania, North Carolina, Virginia, Georgia) where approximately 50% of sales originate would materially adversely affect financial condition and operations.
• Non-compliance with manufacturers' Minimum Advertised Pricing Policies (MAPP) could result in forfeiture of rebates, suspension of future purchases, or termination of business relationships with key suppliers.
• The loss of any key suppliers or vendor cooperative payments would negatively impact the business, financial condition, and results of operations.
• Changes in, or disruptions to, shipping arrangements, including pricing, performance problems, or external factors like natural disasters and labor shortages, could adversely affect the business.
• Failure to provide adequate levels of customer service and support could lead to customer churn and harm the business.
• Website content could expose the company to various liabilities, including negligence, copyright, patent, trademark infringement, and defamation claims.
• Inability to protect intellectual property rights or being found to infringe on the proprietary rights of others could result in substantial costs and harm business.
• Failure or misuse of information systems and customer-facing technology systems, including online payment methods, could disrupt operations, expose to third-party claims, or increase fraud risk.
• Cybersecurity incidents or failure to protect confidential information could damage reputation and brands, leading to significant financial and legal exposure.
• Migration of data and systems to a new information technology platform may disrupt operations, cause service outages, or increase cybersecurity risks.
• Non-compliance with evolving federal and state laws and regulations relating to privacy, data protection, marketing, advertising, and consumer protection could adversely affect the business.
• The company faces the risk of litigation resulting from unauthorized text messages sent in violation of the Telephone Consumer Protection Act.
• Operating results are difficult to predict and may fluctuate due to factors such as customer acquisition/retention, product mix, competition, advertising costs, economic trends, and tariffs.
• Uncertainties in economic conditions and their impact on consumer spending patterns could adversely impact the business, particularly during economic downturns.
• Failure to successfully manage and integrate acquisitions or strategic alliances could have a material adverse effect.
• The market for pet telemedicine is immature and uncertain; if it does not develop as expected, the growth and results of the partnership with Vetster may be adversely affected.
• Evolving foreign trade policy or the imposition of tariffs on imported goods may increase procurement costs and negatively impact financial results.
• Payment-related risks, including increased operating costs, exposure to fraud, and potential liability, could adversely affect business.
• The identified material weaknesses in internal controls over financial reporting and the restatements could lead to regulatory actions, litigation, loss of investor confidence, and a decline in stock price.
• Taxing authorities may successfully assert that the company should have collected additional sales and use taxes, or changes in tax laws could increase the cost of doing business.
• Significant competition from veterinarians and online/traditional retailers, as well as challenges from strategic alliances among competitors, may prevent the company from competing profitably.
• Product recalls and concerns regarding the safety and quality of pet products could damage the company's reputation, lead to decreased sales, or result in product liability claims.
• Pandemics or other health crises, such as a resurgence of COVID-19, may adversely affect business operations and financial results.
• The company's stock price fluctuates and may fall below expectations, potentially leading to litigation and investor losses.
• The ability to issue additional shares of preferred stock could defer a change of control or dilute the interests of common shareholders.
• Certain anti-takeover provisions of Florida law and the company's bylaws could make it more difficult for a third party to acquire the company.
• Actions of activist stockholders could be disruptive and costly, adversely affecting results of operations, financial condition, and/or share price.
• The ability to pay regular dividends is discretionary and may be limited by financial condition or Florida law.

Future Outlook

The company is committed to transforming from a digital-only model to an omnichannel business, with strategic initiatives including expansion into multi-channels like Amazon, new compound pharmacy partnerships, and the launch of private label functional health products in FY2026. Significant investments are planned for modernizing technology, e-commerce infrastructure, and customer experience. The fiscal 2026 marketing strategy aims to integrate brands, increase traffic, and build customer loyalty. However, future sales may be adversely affected by increased competition and consumer price sensitivity, and changes in post-pandemic consumer behavior make predictions challenging. Interest income may decrease due to cash utilization or interest rate changes, and there is a potential for additional goodwill impairment in Q1 FY2026 due to sustained stock price decline.

Management Comments

• "We are executing a series of strategic initiatives that enhance customer experience, optimize operational efficiency, and leverage innovation to drive long-term shareholder value."
• "We believe that a high level of customer care and support is critical in retaining and expanding our customer base."
• "Our goal is to create a concierge customer experience through modern technology that incorporates AI, automation, and product management that drives personalized journeys across all touchpoints."
• "Looking ahead, we are evolving from a digital-only model to a true omnichannel business offering consumers a range of products and services. That means meeting pet parents where they are, however they choose to shop."
• "We are deeply committed to the mission and purpose that has driven our business from the start."
• "Our distinct advantage lies in our 29 years of expertise, delivered through our team of highly qualified pharmacists and technicians with specialized training in veterinary pharmacology that are licensed across all fifty states."
• "The Board of Directors determined to reserve and/or utilize cash resources that would otherwise be available for distributions in order to fund additional strategic transactions or investments in our business."

Industry Context

The pet industry is a vast and continuously expanding market, with U.S. pet spending reaching $152 billion in 2024, of which veterinary care and prescription medications accounted for $39.8 billion. However, recent industry reports indicate muted pet household adoptions and pricing pressure, leading to reduced vet visits and spending at pet retail. The company operates in a rapidly evolving, highly competitive, and fragmented business environment, facing competition from veterinarians, local and national chain specialty retailers, and direct-to-consumer offerings from vendors. The entrance of several large retailers into the pet pharmacy space further intensifies competition. The market for pet telemedicine, while growing, remains immature and uncertain, with demand influenced by factors such beyond the company's control, such as technology adoption, competitive offerings, and ease of use.

Comparison to Industry Standards

• The company's total shareholder return (TSR) for Performance Stock Units (PSUs) is benchmarked against the S&P 600 Specialty Retail Index.
• The peer group for FY2025 executive compensation benchmarking included sixteen companies: Medifast, Inc., Nature's Sunshine Products, Inc., GrowGeneration Corp., CarParts.com, Inc., The Honest Company, Inc., LifeVantage Corporation, The RealReal, Inc., ThredUp Inc., Mannatech, Incorporated, Purple Innovation, Inc., Weyco Group, Inc., Natural Alternatives International, Inc., Groupon, Inc., Rent the Runway, Inc., BARK, Inc., and Grove Collaborative Holdings, Inc.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in routine litigation and administrative complaints incidental to its business, including claims related to products, product warranties, contracts, employment, intellectual property, consumer protection, and pharmacy and other regulatory matters. Management believes none are likely to have a material adverse effect.
• On April 18, 2024, a class-action lawsuit was filed by Timothy Fitchett in Pennsylvania, alleging violations of the state's Unfair Trade Practices and Consumer Protection Law by misrepresenting 'reg. prices' for products never sold at those prices. The company denies liability and intends to defend the action.
• On February 14, 2025, a class-action lawsuit was filed by Ashley Bird, Tyler Dvornski, and Tiffany Hughes in New York, alleging misrepresentation of 'sale' prices with strikethrough prices never used, artificially inflating prices, violating New York General Business Law and California's Unfair Competition Law and False Advertising Law. The company denies liability and intends to defend the action.

Related Party Transactions

• On September 29, 2024, the company entered into a master services agreement with Fabric, Inc. for cloud-based product services. Sandra Campos, the company's former Chief Executive Officer and President, was an equity-holder in Fabric, Inc. and served on its Board of Directors during the twelve months ended March 31, 2025. The transaction was reviewed and approved by the company's Audit Committee. The company paid $105 thousand related to this contract in fiscal year 2025.

Stakeholder Impact

• Shareholders: Negative impact from the financial restatement, significant decline in sales and Adjusted EBITDA, and the indefinite suspension of dividends. Positive impact from new leadership and comprehensive remediation plans aimed at improving governance and long-term value. Anti-takeover provisions and preferred stock purchase rights may limit potential acquisition premiums.
• Employees: Directly impacted by the resignations of the former CEO and CFO. The company is emphasizing fostering a supportive and inclusive environment, with ongoing training, competitive benefits, and a reinforced whistleblower policy.
• Customers: Affected by past issues such as accelerated AutoShip shipments and coupon promotion problems. The company is focusing on enhancing customer experience, expanding product offerings, and improving customer care and support.
• Vendors/Suppliers: Relationships are critical for inventory sourcing, with compliance to Minimum Advertised Pricing Policies (MAPP) being important. Past accounting errors related to vendor agreements highlight the need for clearer communication and adherence to terms.
• Regulatory Bodies: Increased scrutiny from the SEC and other regulatory authorities due to the financial restatement, material weaknesses in internal controls, and ongoing legal proceedings. The company's remediation efforts are aimed at achieving and maintaining compliance.

Next Steps

• Implement additional and enhanced policies, procedures, and training on the Company’s Code of Ethics & Conduct.
• Strengthen internal controls over financial reporting and operations related to the matters investigated by the Audit Committee.
• Continue to modernize digital technology infrastructure, including e-commerce platforms, call centers, order management systems (OMS), pharmacy systems, and fulfillment and inventory management capabilities.
• Integrate the PetMeds and PetCareRx brands as part of the fiscal 2026 marketing strategy to increase customer website traffic and build loyalty.
• Launch the private label assortment on Amazon in early FY2026.
• Introduce private label functional health products across multi channels in the latter part of FY2026.
• Conduct internal training courses over Sarbanes-Oxley regulations and the Company’s internal control over financial reporting program for relevant personnel.
• Engage third-party experts, as necessary, to assist management with the review of accounting treatment and financial reporting for significant, complex, or non-recurring transactions.
• Establish a Disclosure Committee comprised of senior management representatives to review all quarterly and annual SEC filings for completeness and accuracy.
• Design and implement additional controls over revenue recognition, specifically relating to the AutoShip program.
• Enhance policies, procedures, and process-level controls for gathering and analyzing facts related to cooperative advertising and vendor contracts.
• Hold the 2025 Annual Meeting of Shareholders virtually on January 21, 2026.
• Monitor for potential future goodwill impairment during the first fiscal quarter of 2026 due to the sustained decline in common stock price.

Key Dates

Recommendation

The company is navigating a period of significant upheaval, marked by a financial restatement, an adverse audit opinion on internal controls, and a substantial decline in key financial metrics like sales and Adjusted EBITDA. The internal investigation uncovered serious governance and operational issues, leading to a complete overhaul of executive leadership. While the new management is implementing comprehensive remediation plans and the company maintains a healthy cash balance with no debt, the path to recovery is uncertain and will require sustained execution to restore investor confidence and improve financial performance. The indefinite suspension of dividends further reduces immediate shareholder returns. A 'Hold' recommendation is appropriate given the high level of uncertainty and the need to observe the effectiveness of the new leadership and remediation efforts over the coming quarters before making a more definitive investment decision.

Keywords

PetMed Express, PETS, SEC filing, 10-K, financial restatement, internal controls, corporate governance, executive changes, pet health, online pharmacy, pet medications, PetCareRx, Vetster, e-commerce, animal health, shareholder rights, anti-takeover, stock compensation, audit committee, risk factors, Adjusted EBITDA, sales decline